{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:49Z","timestamp":1783850209230,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":660,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jtct.2021.04.021","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T13:52:47Z","timestamp":1620222767000},"page":"684.e1-684.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection"],"prefix":"10.1016","volume":"27","author":[{"given":"Emily S.","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Shing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Yoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Pergam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar N.J.","family":"Pipavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.04.021_bib0001","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.04.021_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","article-title":"An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group","volume":"37","author":"Denning","year":"1998","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2021.04.021_bib0003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.04.021_bib0004","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood.V84.8.2811.2811","article-title":"Hepatosplenic candidiasis\u2014a contraindication to marrow transplantation?","volume":"84","author":"Bjerke","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.021_bib0005","first-page":"265","article-title":"Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases","volume":"13","author":"Martino","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0006","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1365-2141.2001.02747.x","article-title":"Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens","volume":"113","author":"Hermann","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbmt.2004.02.006","article-title":"Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center","volume":"10","author":"Fukuda","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/520274","article-title":"Impact of previous aspergillosis on the outcome of bone marrow transplantation","volume":"26","author":"Offner","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.04.021_bib0009","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.04.021_bib0010","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.transproceed.2008.03.149","article-title":"Hematopoietic stem cell transplantation in patients with active fungal infection: not a contraindication for transplantation","volume":"40","author":"Aki","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jtct.2021.04.021_bib0011","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study","volume":"95","author":"Cordonnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.04.021_bib0012","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bmt.2016.259","article-title":"Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study","volume":"52","author":"Maziarz","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0013","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood-2006-03-008706","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.021_bib0014","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/bmt.2015.237","article-title":"Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties","volume":"51","author":"Penack","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bmt.2015.302","article-title":"Invasive aspergillosis before HCT: safe to proceed?","volume":"51","author":"Avery","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0016","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428194.2019.1660977","article-title":"Granulocyte transfusions \u2013 bridging to allogeneic hematopoietic stem cell transplantation","volume":"61","author":"Nguyen","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.04.021_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-018-0317-4","article-title":"Refining AML outcome prediction","volume":"33","author":"Hourigan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.04.021_bib0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41409-019-0739-2","article-title":"Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"55","author":"Hoffmann","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0019","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms","volume":"32","author":"Halpern","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.04.021_bib0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.04.021_bib0021","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbmt.2008.04.011","article-title":"Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes","volume":"14","author":"Scott","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0022","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00277-004-0965-5","article-title":"Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes","volume":"84","author":"Yamaguchi","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0023","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2013.10.008","article-title":"Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia","volume":"26","author":"Appelbaum","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MOH.0000000000000543","article-title":"Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia","volume":"26","author":"Fasan","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/10428194.2011.603445","article-title":"Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: Impact of patient characteristics and timing of transplant","volume":"53","author":"Spina","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.04.021_bib0026","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2021.04.021_bib0027","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s10875-018-0539-2","article-title":"Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults","volume":"38","author":"Corvilain","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0028","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2014.60.5121","article-title":"Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial","volume":"33","author":"Wan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0029","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials","volume":"23","author":"Clark","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/imj.12598","article-title":"Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Blyth","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtct.2021.04.021_bib0031","doi-asserted-by":"crossref","first-page":"eaat8410","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2021.04.021_bib0032","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cncr.31914","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma","volume":"125","author":"Calip","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2021.04.021_bib0033","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","article-title":"The colony-stimulating factors and cancer","volume":"1","author":"Metcalf","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2021.04.021_bib0034","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.021_bib0035","article-title":"Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction","volume":"4","author":"Estcourt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2021.04.021_bib0036","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2015.53","article-title":"Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience","volume":"50","author":"Nikolajeva","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0037","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.14597","article-title":"Granulocyte transfusions in the management of invasive fungal infections","volume":"177","author":"West","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.04.021_bib0038","first-page":"501","article-title":"Historical perspectives, current status, and ethical issues in granulocyte transfusion","volume":"47","author":"Klein","year":"2017","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.jtct.2021.04.021_bib0039","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/vox.12835","article-title":"Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation","volume":"114","author":"Berglund","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtct.2021.04.021_bib0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41409-018-0344-9","article-title":"Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Kongtim","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.021_bib0041","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:41Z","timestamp":1763002781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721008824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2666636721008824"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}